|
Age of IBD diagnosis (years)
|
25.81 ± 12.45
|
|
Age at anti-TNF therapy initiation (years)
|
31.35 ± 13.59
|
|
Follow up (months)
|
48.54 ± 36.48
|
|
Sex (male:female)
|
940:494
|
|
IBD type (UC:CD)
|
332 (23.2%):1102 (76.8%)
|
|
History of smoking (no:yes)
|
991 (69.1%):443 (30.9%)
|
|
Anti-TNF agents
| |
|
One
|
1259 (87.8%)
|
|
Infliximab
|
939 (65.5%)
|
|
Adalimumab
|
311 (21.7%)
|
|
Golimumab
|
9 (0.6%)
|
|
Two
|
172 (12.0%)
|
|
Infliximab, Adalimumab
|
166 (11.6%)
|
|
Infliximab, Golimumab
|
2 (0.1%)
|
|
Adalimumab, Golimumab
|
4 (0.3%)
|
|
Three
|
3 (0.2%)
|
|
LTBI diagnosis
| |
|
Done
|
1333 (93.0%)
|
|
Negative
|
1135 (85.1%)
|
|
Positive
|
198 (14.9%)
|
|
Completion of TB prophylaxis
|
190 (96%)
|
|
Failure to complete TB prophylaxis
|
8 (4.0%)
|
|
Not done, other
|
101 (7.0%)
|
